TQB3909 and azacitidine for myeloid cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new oral drug, TQB3909, combined with a standard chemotherapy drug (azacitidine) for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML or MDS (but not a specific type called acute promyelocytic leukemia).
- You are 18 years or older.
- You are expected to live at least 3 months.
- Your major organs (like heart, kidneys, liver) are working well.
- You can take oral medication and do not have issues absorbing medicines.
- You have not had another cancer in the last 3 years (except some minor skin or cervical cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new tablet, TQB3455, for people with certain blood cancers (MDS or AML) that have an IDH2 mutation. The goal is to see if the drug can help when other treatments haven't worked or aren't possible.
This trial tests an oral medication (NTQ2494) for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. It aims to see if the drug is safe and effective.
This trial tests a new daily tablet (TQB3911) for people with chronic myeloid leukemia (CML) whose current targeted therapy (TKI) has stopped working or caused side effects. The goal is to see if this new drug is safe and can better control the leukemia.
This trial tests a new drug (ICP-248) combined with standard treatment azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). It aims to find out if the combo is safe and effective for those who haven't been helped by other treatments or cannot have strong chemotherapy.
This trial tests a new drug called axatilimab, given alone or with another drug, for people with certain blood cancers that are advanced or hard to treat. The goal is to see if this combination can help control the disease.
This trial tests a combination of two medicines (called MA+AZA) for people who have just been diagnosed with acute myeloid leukemia (AML). It aims to see if this treatment can help control the disease and improve outcomes.
Hear when a new Myeloid Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.